Free Trial
OTCMKTS:BMXMF

bioMérieux (BMXMF) Stock Price, News & Analysis

bioMérieux logo
$100.50 -1.89 (-1.85%)
(As of 11/22/2024 ET)

About bioMérieux Stock (OTCMKTS:BMXMF)

Key Stats

Today's Range
$100.50
$100.50
50-Day Range
$102.39
$122.50
52-Week Range
$93.50
$122.52
Volume
28 shs
Average Volume
556 shs
Market Capitalization
$11.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Receive BMXMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bioMérieux and its competitors with MarketBeat's FREE daily newsletter.

BMXMF Stock News Headlines

bioMérieux S.A. (BMXMF)
Buffett Dumps $982 Million in BofA Stock—What Does He Know?
Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.
Berenberg Bank Keeps Their Buy Rating on bioMerieux (0RUG)
Kepler Capital Reaffirms Their Buy Rating on bioMerieux (0RUG)
bioMerieux (0RUG) Gets a Buy from Kepler Capital
See More Headlines

BMXMF Stock Analysis - Frequently Asked Questions

bioMérieux's stock was trading at $108.50 at the start of the year. Since then, BMXMF shares have decreased by 7.4% and is now trading at $100.50.
View the best growth stocks for 2024 here
.

Shares of BMXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:BMXMF
CIK
N/A
Employees
14,600
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.98 billion
Cash Flow
$5.17 per share
Book Value
$34.31 per share

Miscellaneous

Free Float
N/A
Market Cap
$11.90 billion
Optionable
Not Optionable
Beta
0.83

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (OTCMKTS:BMXMF) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners